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ABSTRACT 
BACKGROUND: ACE-inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) have become 
cornerstones of therapy for chronic heart failure (CHF). Guidelines advise high target doses for 
ACEIs/ARBs, but fear of worsening renal function may limit dose titration in patients with 
concomitant chronic kidney disease (CKD).  
METHODS: In this retrospective observational study, we identified 722 consecutive patients with 
systolic CHF, stable CKD stage III/IV (eGFR 15-60mL/min/1.73m²) and chronic ACEI/ARB 
treatment from the out-patient heart failure clinics at the Universities of Hull, UK and Heidelberg, 
Germany. Change of renal function, worsening CHF and hyperkalemia at 12 month follow-up were 
analyzed as a function of both baseline ACEI/ARB dose and dose-change from baseline.  
RESULTS: ΔeGFR was not related to baseline dose of ACEI/ARB (P=0.58), nor to relative (P=0.18) 
or absolute change of ACEI/ARB dose (P=0.21) during follow-up. Expressing change of renal 
function as a categorical variable (improved/stable/decreased) as well as subgroup analyses with 
respect to age, sex, NYHA, left ventricular ejection fraction, diabetes, concomitant aldosterone 
antagonists, CKD-stage, hypertension, ACEI vs. ARB, and congestion status yielded similar results. 
There was no association of dose/dose-change with incidence of either worsening CHF or 
hyperkalemia. 
CONCLUSIONS: In patients with systolic CHF and stable CKD stage III/IV, neither continuation of 
high doses of ACEI/ARB nor up-titration were related to adverse changes in longer-term renal 
function. Conversely, down-titration was not associated with improvement in eGFR. Use of high doses 
of ACEI/ARB and their up-titration in patients with CHF and CKD III/IV may be appropriate 
provided the patient is adequately monitored. 
Words: 249  
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INTRODUCTION 
In patients with chronic systolic heart failure (CHF), concomitant chronic kidney disease (CKD) is 
common and conveys a poor prognosis (1-4). Blockade of the renin-angiotensin-system (RAS) with 
angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) has been a 
guideline recommended cornerstone for the management of both CKD and CHF for the last 25 years 
(4-7). 
As impaired renal function may adversely affect metabolism and elimination of ACEIs/ARBs (8-11), 
trials of CHF generally excluded patients with severe CKD. Thus, surprisingly little is known about 
how to manage patients suffering from both CHF and CKD (12). International guidelines for CHF 
advise high target doses of ACEIs/ARBs in order to reduce CHF morbidity and mortality (13). Higher 
doses of RAS-blockade, on the other hand, may be associated with higher rates of renal complications 
in patients with CHF (14, 15). In contrast, guidelines for renal disease do not specify target doses of 
ACEIs/ARBs (16). Then again, there is a general recommendation that lower doses should be used in 
patients with CKD to prevent hyperkalemia and acute renal failure (8-11). 
ACEIs/ARBs cause constriction of the post-glomerular efferent arteriole, and current evidence 
supports their use for renal protection particularly in patients with diabetes and/ or hypertension (16, 
17, 24). Here, CKD is caused by sclerosis of the glomeruli, and ACEIs/ARBs improve renal function 
by lowering glomerular pressure (9-11). In CHF patients in contrast, renal venous congestion and a 
fall in the trans-renal pressure gradient mainly contribute to the development and progression of CKD 
(1). Thus, ACEIs/ARBs may have differential effects on renal function depending on the underlying 
pathophysiology of CKD. 
There are no clinical trials randomizing different ACEI/ARB doses to patients with either CKD alone 
or as a complication of CHF. The optimal dosing strategy in these patients for renal protection or for 
safety endpoints such as worsening CHF and hyperkalemia is unknown. We therefore sought to 
explore the association of baseline dose and subsequent dose titration of ACEIs/ARBs with renal 
function, worsening CHF and hyperkalemia in a retrospective cohort of CHF out-patients with reduced 
ejection fraction and CKD stage III/IV. 
4 
 
 
METHODS 
PATIENT SELECTION 
We retrospectively identified 722 consecutive patients with stable CHF due to chronic systolic 
dysfunction and concomitant stable CKD stage III/IV who attended the community heart failure 
clinics of the Department of Academic Cardiology, University of Hull, UK, or the University Hospital 
Heidelberg, Germany, between May 1995 and March 2012 who met the following inclusion criteria: 
1. A diagnosis of CHF based on relevant symptoms and signs supported by objective evidence of 
substantial abnormalities of cardiac function on imaging or invasive hemodynamics (13). 
2. Systolic dysfunction defined as a left ventricular ejection fraction (LVEF) <45%.  
3. Assessment of renal function both at baseline and at 12 months follow-up. 
4. CKD was defined according to the KDIGO practice guidelines (16) as a low glomerular 
filtration rate (GFR) present for at least 3 months. All patients suffered from either stage III or 
stage IV CKD at baseline. Stage III CKD was defined as a GFR of 30 – 60 mL/min/1,73m², 
while stage IV CKD was defined as a GFR of 15 – 29 mL/min/1,73m² (17). The GFR was 
estimated using the Modification of Diet in Renal Disease (MDRD) Study equation. 
Performance accuracy of the MDRD formula for estimation of GFR was shown to be highly 
accurate in patients with GFR <60 mL/min/1,73m² (18). 
5. Stable medication with ACEIs or ARBs for at least 1 month prior to inclusion. 
And none of the exclusion criteria: 
1. Cardiac decompensation requiring inotropic support in the previous 3 months. 
2. A history of primary or severe concomitant valve disease. 
3. Requirement of renal replacement therapy.  
4. Estimated GFR (eGFR) <15 mL/min/1.73m² at baseline.  
Medication was at the discretion of the referring physician with respect to guideline recommended 
drugs. Target doses and dose equivalents for ACEIs and ARBs were derived from ESC guidelines for 
the diagnosis and treatment of acute and chronic heart failure (13). For example, daily doses of 10 mg 
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ramipril or 32 mg candesartan were both considered as 100% dose equivalent, while 5 mg ramipril and 
16 mg candesartan were defined as 50% dose equivalent. 
The study conformed to the principles outlined in the Declaration of Helsinki and was approved by the 
local ethics committees. All patients gave their written informed consent for their data to be recorded 
and used for research purposes. No extramural funding was used to support this work. The authors are 
solely responsible for the design and conduct of this study, all study analyses, the drafting and editing 
of the paper and its final contents. 
 
FOLLOW-UP AND ENDPOINTS 
Patient follow-up was by scheduled visits to the respective outpatients’ clinics. The predefined 
primary endpoint for the purpose of this study was the change of renal function as defined by the 
change in eGFR at 12 months’ follow-up. Secondary/safety endpoints were hospitalization due to 
worsening CHF and significant hyperkalemia (serum potassium >5.5 mmol/L) between visits. The 
follow-up visit for the primary purpose of the present analysis occurred at 365 (353-377) days. The 
frequency of additional interim follow-up visits and follow-up blood samples were at the discretion of 
the responsible physician with respect to guideline recommendations and the patients’ individual risk 
factors for worsening renal function and/or hyperkalemia. Medication was recorded and serum 
creatinine levels measured at each visit.  
Secondary endpoint status was determined at the follow-up visit and verified either through electronic 
hospital records or telephone calls to the patients’ physicians. 
In order to ensure that all included patients were on ACEI/ARB treatment for at least 4 weeks at the 
time of study inclusion the baseline visit was defined as the (at least) second consecutive visit to the 
heart failure outpatient department that reported ACEI/ARB treatment AND offered complete 
information on ACEI/ARB dosing, eGFR, hospitalization due to worsening CHF, and serum 
potassium measurements.   
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SUBGROUPS 
All analyses were repeated in pre-specified subgroups with respect to age (≤median vs. >median), sex 
(male vs. female), NYHA functional class (I/ II vs. III/ IV), LVEF (≤35% vs. >35%) diabetes (yes vs. 
no), concomitant therapy with aldosterone antagonists (MRA) (yes vs. no), stage of CKD (stage IV: 
eGRF 15-29 mL/min/1.73m² vs. stage III: eGFR 30-59 mL/min/1.73m²), hypertension (yes vs. no), 
type of RAS blockade (ACEI vs. ARB), and admission for worsening CHF between visits (yes vs. no). 
STATISTICS 
Descriptive statistics and comparative statistics were obtained using MedCalc software version 12.7 
(Ostend, Belgium). Results are displayed using GraphPad Prism version 6.02 for Windows (La Jolla, 
California, USA). All tests are two-tailed and an arbitrary P value of less than 5% was regarded as 
statistically significant. The data are presented as mean ± SD, median [interquartile range], or number 
(%) as appropriate. To compare frequencies and 12 months hospitalization rates, chi-squared analysis 
was performed. To test for significant differences between two groups, the two-sample Wilcoxon test 
and Student’s t test were used where appropriate. To test for significant differences between more than 
two groups, the Kruskal-Wallis test and analyses of variance (ANOVA) were used.  
 
In order to analyze the association of ACEI/ARB dose equivalents at baseline and renal function, 
different strategies were applied: ACEI/ARB dose equivalents were entered into the analyses both as a 
continuous variable and as a categorical variable – stratified in 3 groups as follows: low-dose: ≤33%, 
moderate-dose: 34-66%, and high-dose: >66% of the maximum recommended dose equivalent from 
CHF guidelines (13).  
 
We analyzed mean change in eGFR at 12 months with respect to baseline ACEI/ARB dose 
equivalents and changes of these dose equivalents from baseline. When analyzing the ACEI/ARB dose 
equivalent as a categorical variable, down-titration was defined as a reduction of ACEI/ARB dose 
equivalent to a different dose group. Similarly, up-titration was defined as an increase of ACEI/ARB 
dose equivalent to a different dose group. Furthermore, we compared ACEI/ARB dosing between 
patients who experienced a pre-specified alteration of renal function in absolute values (∆eGFR >± 
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10mL/min/1.73m² vs. ∆eGFR ≤±10 mL/min/1.73m²) or relative values (∆eGFR >±10% vs. ∆eGFR 
≤±10%).  
 
When treating ACEI/ARB dosing as a continuous variable, linear regression analyses were performed 
to evaluate the relation between ACEI/ARB dosing and eGFR. These included ACEI/ARB dose 
equivalents at baseline, absolute changes of ACEI/ARB dose equivalents, and relative changes of 
ACEI/ARB dose equivalents together with absolute changes of eGFR and relative changes of eGFR. 
 
 
RESULTS 
BASELINE CHARACTERISTICS 
A total of 722 patients was included, 341 (47%) from Hull and 381 (53%) from Heidelberg. Of these, 
148 patients (20.5%) received low-dose, 235 patients (32.5%) moderate-dose, and 339 patients 
(47.0%) high-dose ACEI/ARB at baseline. 
Age, mean eGFR and serum potassium concentrations were similar in each dose group (Table 1). 
Although LVEF was higher in patients with low-dose ACEI/ARB treatment, NTproBNP levels were 
higher and 6 minute walk test distance was shorter.  
Over 12 months of follow-up, mean eGFR was stable in the overall population (ΔeGFR 0.51 (-7.06 – 
8.57 ml/min/1.73m²)), and 140 (19%), 439 (61%) and 143 (20%) patients had doses of ACEI/ARBs 
reduced, maintained or increased. 
 
Table 1: Baseline characteristics with respect to ACEI/ARB dose equivalents 
  
All patients 
(n = 722) 
Low-dose 
(n = 148) 
Moderate-dose 
(n = 235) 
High-dose 
(n = 339) 
P value 
Men (n, %) 493 (68) 85 (57) 161 (68) 247 (73) 0.003 
Age (years) 69 ± 11 69 ± 13 69 ± 10 69 ± 11 0.93 
Diabetes (n, %) 206 (30) 37 (26) 62 (27) 107 (33) 0.23 
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Table 1: Baseline characteristics with respect to ACEI/ARB dose equivalents 
Hypertension (n, %) 424 (59) 80 (54) 131 (56) 213 (63) 0.10 
COPD (n, %) 133 (18) 25 (17) 51 (22) 57 (17) 0.29 
NYHA (n, %) 
    
0.13 
I 87 (12) 13 (9) 23 (10) 51 (15) 
 
II 329 (46) 62 (42) 103 (44) 164 (49) 
 
III 289 (40) 69 (47) 103 (44) 117 (35) 
 
IV 11 (2) 4 (3) 3 (1) 4 (1) 
 
BMI (kg/m²) 28.0 ± 5.2 27.2 ± 5.2 27.5 ± 5.0 28.6 ± 5.3 0.006 
SBP (mmHg) 121 ± 24 122 ± 27 119 ± 23 122 ± 23 0.20 
DBP (mmHg) 72 ± 13 71 ± 14 72 ± 12 73 ± 13 0.28 
HR (1/min) 72 ± 15 74 ± 14 72 ± 15 71 ± 15 0.11 
LVEF (n, %) 32 ± 12 34 ± 12 30 ± 12 32 ± 12 0.009 
LVEDD (mm) 34 ± 27 26 ± 25 38 ± 28 35 ± 26 <0.001 
6 MWT (m) 360 ± 141 314 ± 144 353 ± 141 382 ± 136 <0.001 
eGFR 
(mL/min/1.73m²) 
47 ± 10 46 ± 11 47 ± 10 48 ± 9 0.01 
Sodium (mmol/L) 139 ± 3 138 ± 3 139 ± 3 139 ± 3 0.09 
Potassium (mmol/L) 5 ± 1 5 ± 3 5 ± 1 5 ± 1 0.68 
Urea (mmol/L)  6.8 ± 5.7 5.8 ± 6.0 7.3 ± 5.7 6.8 ± 5.5 0.05 
NTproBNP (pmol/L) 
186 
(77-444) 
257 
(90-609) 
246 
(82-480) 
150 
(73-361) 
0.002 
ACEI (n, %) 559 (77) 94 (64) 171 (73) 294 (87) <0.001 
ARB (n, %) 163 (23) 54 (36) 64 (27) 45 (13) <0.001 
Beta blocker (n, %) 567 (79) 106 (72) 188 (80) 273 (81) 0.07 
Beta blocker dose 
equivalent* (n, %) 
50 (25-100) 25 (19-50) 50 (25-95) 50 (38-100) <0.001 
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Table 1: Baseline characteristics with respect to ACEI/ARB dose equivalents 
MRA (n, %) 352 (49) 66 (45) 109 (46) 177 (52) 0.50 
Digitalis (n, %) 180 (25) 38 (26) 62 (26) 80 (24) 0.73 
Loop diuretic (n, %) 590 (82) 126 (85) 185 (79) 279 (82) 0.73 
Loop diuretic (mg 
furosemide) 
60 (40-80) 40 (40-80) 60 (40-80) 80 (40-80) 0.60 
Aspirin (n, %) 157 (22) 35 (24) 45 (19) 77 (23) 0.49 
Warfarin (n, %) 372 (52) 62 (42) 128 (54) 182 (54) 0.03 
Statin (n, %) 434 (60) 77 (52) 144 (61) 213 (63) 0.07 
Allopurinol (n, %) 120 (17) 16 (11) 40 (17) 64 (19) 0.09 
ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; SD, standard deviation; COPD, chronic obstructive 
pulmonary disease; NYHA, New York Heart Association functional class; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, 
heart rate; LVEF, left ventricular ejection fraction; LVEDD, left ventricular enddiastolic diameter; 6 MWT, 6 minute walk test; eGFR, 
estimated glomerular filtration rate calculated using the Modification of Diet in Renal Disease equation; MRA, mineralocorticoid receptor 
antagonist. *Beta blocker dose equivalents were derived from ESC guidelines for the diagnosis and treatment of acute and chronic heart 
failure (13). For example, daily doses of 10 mg bisoprolol or 50 mg carvedilol were both considered as 100% dose equivalent 
 
CHANGE OF eGFR AS A FUNCTION OF ACEI/ARB DOSE EQUIVALENTS   
There was no difference in the mean change of eGFR at 12 months amongst the three baseline 
ACEI/ARB dose groups. Neither up-titration, maintenance of the same dose, nor down-titration of 
ACEI/ARBs was associated with change in eGFR at 12 months (Figure 1).  
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Figure 1: Change of eGRF as a function of ACEI/ARB dose equivalents at baseline and subsequent 
dose changes. 
eGFR, estimated glomerular filtration rate using the Modification of Diet in renal Disease equation; ACEI, angiotensin converting enzyme 
inhibitor; ARB, angiotensin receptor blocker. 
 
 
Linear regression analyses showed no relationship between either change in eGFR and ACEI/ARB 
dose equivalents at baseline or change in eGFR and change in ACEI/ARB dose equivalents (Table 2, 
Figures 2 a) and b)). 
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Table 2: Regression analyses of change in renal function as a function of ACEI/ARB dosing in the 
complete sample 
  
ACEI/ARB dose 
equivalent at baseline 
ΔACEI/ARB dose 
equivalent (abs.) 
  Beta P value Beta P value 
ΔeGFR (abs.) 0.04 0.26 0.04 0.21 
ΔeGFR (%) 0.02 0.58 0.04 0.21 
eGFR, estimated glomerular filtration rate using the Modification of Diet in renal Disease equation; 
ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker. 
 
 
Figure 2: Relationship between a) absolute change in eGFR and relative change in ACEI/ARB dose 
equivalents; b) relative change in eGFR and relative change in ACEI/ARB dose equivalents. 
eGFR, estimated glomerular filtration rate using the Modification of Diet in renal Disease equation; ACEI, angiotensin converting enzyme 
inhibitor; ARB, angiotensin receptor blocker. 
 
CHANGE OF eGFR AS A FUNCTION OF PREDEFINES CHANGES OF eGFR  
The proportion of patients who experienced a change in eGFR was similar between baseline dose 
groups, expressed either in absolute terms or as change relative to baseline, irrespective of subsequent 
change in ACEI/ARB dose (P = 0.65) (Tables 3 and 4). 
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Table 3: Number of patients with a pre-specified alteration of eGFR (absolute values) as a function of 
ACEI/ARB dosing strategy 
ACEI/ARB 
dose at 
baseline 
ACEI/ARB 
dose after 12 
months  
∆eGFR after 12 months (%) 
Decrease >10 
mL/min/1.73m² 
Stable (≤ ± 10 
mL/min/1.73m²) 
Increase >10 
mL/min/1.73m² 
Low-dose  
(n = 148) 
Withdrawal  
(n = 20) 
5 (25) 8 (40) 7 (35) 
Maintenance 
(n = 63) 
14 (22) 36 (57) 13 (21) 
Up-titration 
(n = 65) 
11 (17) 37 (57) 17 (26) 
Moderate-dose 
(n = 235)  
Down-titration 
(n = 48) 
9 (19) 28 (58) 11 (23) 
Maintenance 
(n = 109) 
15 (14) 69 (63) 25 (23) 
Up-titration 
(n = 78) 
16 (21) 46 (59) 16 (21) 
High-dose  
(n = 339) 
Down-titration 
(n = 72) 
17 (24) 40 (56) 15 (21) 
Maintenance 
(n = 267) 
37 (14) 172 (64) 58 (22) 
n  124 436 162 
ACEI, angiontensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; eGFR, estimated glomerular filtration rate using the 
Modification of Diet in Renal Disease equation; n, number of patients. 
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Table 4: Number of patients with a pre-specified alteration of eGFR (relative/% values) as a function 
of ACEI/ARB dosing strategy 
ACEI/ARB dose 
at baseline 
ACEI/ARB dose 
after 12 months 
∆eGFR after 12 months (%) 
Decrease >10% 
Stable 
(≤ ± 10%) 
Increase 
>10% 
Low-dose 
(n = 148) 
Withdrawal 
(n = 20) 
6 (30) 5 (25) 9 (45) 
Maintenance 
(n = 63) 
25 (40) 16 (25) 22 (35) 
Up-titration 
(n = 65) 
25 (38) 20 (31) 20 (31) 
Moderate-dose 
(n = 235) 
Down-titration 
(n = 48) 
20 (42) 12 (25) 16 (33) 
Maintenance 
(n = 109) 
33 (30) 38 (35) 38 (35) 
Up-titration 
(n = 78) 
26 (33) 25 (32) 27 (35) 
High-dose 
(n = 339) 
Down-titration 
(n = 72) 
24 (33) 26 (36) 22 (31) 
Maintenance 
(n = 267) 
72 (27) 94 (35) 101 (38) 
n  231 236 255 
ACEI, angiontensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; eGFR, estimated glomerular filtration rate using the 
Modification of Diet in Renal Disease equation; n, number of patients. 
 
SUBGROUPS 
We did not find any relation between renal function and ACEI/ARB dose in any of the pre-specified 
subgroups (Tables 5 and 6). 
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Table 5: Linear regression analyses of absolute change of eGFR (dependent variable) as a 
function of ACEI/ARB dosing strategy in pre-specified subgroups  
Subgroup 
ACEI/ARB dose at 
baseline 
∆ACEI/ARB dose 
(abs.) 
∆ACEI/ARB dose 
(%) 
Beta P-value Beta P-value Beta P-value 
Age 
≤median -0.06 0.28 0.06 0.35 0.01 0.90 
>median 0.08 0.09 -0.02 0.75 0.03 0.56 
Sex 
male 0.01 0.83 0.04 0.40 0.01 0.86 
female 0.03 0.63 -0.01 0.83 0.02 0.74 
NYHA 
I/ II 0.03 0.56 0.07 0.19 0.07 0.14 
III/ IV 0.01 0.89 -0.04 0.52 -0.06 0.30 
LVEF 
≤35% -0.01 0.80 -0.01 0.81 -0.04 0.41 
>35% 0.01 0.86 0.08 0.27 0.08 0.29 
Diabetes 
yes 0.11 0.11 -0.07 0.35 -0.01 0.92 
no -0.01 0.80 0.05 0.31 0.03 0.56 
MRA 
yes -0.02 0.72 0.06 0.28 0.03 0.64 
no 0.05 0.30 -0.01 0.85 0.02 0.73 
CKD 
stage III 0.05 0.17 0.02 0.60 0.01 0.86 
stage IV -0.12 0.41 0.05 0.74 0.03 0.85 
RR ↑ 
yes 0.03 0.61 0.09 0.11 0.06 0.31 
no 0.00 0.99 -0.06 0.27 -0.02 0.72 
RAS 
blockade 
ACEI 0.00 0.94 -0.00 0.96 -0.04 0.40 
ARB 0.09 0.24 0.10 0.24 0.12 0.14 
Worsening 
CHF 
yes 0.08 0.45 0.21 0.06 0.16 0.14 
no -0.01 0.91 -0.01 0.75 -0.00 0.99 
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ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; NYHA, New York Heart Association; LVEF, left 
ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; CKD, chronic kidney disease; RR↑, hypertension; RAS, renin 
angiotensin system. 
 
 
Table 6: Linear regression analyses of relative (%) change of eGFR (dependent variable) as a 
function of ACEI/ARB dosing strategy in pre-specified subgroups 
Subgroup 
ACEI/ARB dose at 
baseline 
∆ACEI/ARB dose 
(abs.) 
∆ACEI/ARB dose 
(%) 
Beta P-value Beta P-value Beta P-value 
Age 
≤median -0.10 0.09 0.05 0.41 0.04 0.45 
>median 0.08 0.13 -0.02 0.73 0.04 0.49 
Sex 
male 0.00 0.93 0.02 0.73 0.01 0.91 
female -0.01 0.86 0.02 0.83 0.05 0.44 
NYHA 
I/ II 0.03 0.54 0.05 0.32 0.08 0.11 
III/ IV -0.03 0.60 -0.01 0.83 -0.01 0.92 
LVEF 
≤35% -0.03 0.57 -0.02 0.65 -0.05 0.39 
>35% -0.03 0.65 0.11 0.13 0.17 0.02 
Diabetes 
yes 0.10 0.17 -0.03 0.68 0.01 0.90 
no -0.04 0.42 0.03 0.52 0.05 0.29 
MRA 
yes -0.04 0.48 0.05 0.42 0.06 0.31 
no 0.03 0.58 -0.00 0.95 0.04 0.46 
CKD 
stage III 0.05 0.17 0.01 0.73 0.01 0.77 
stage IV -0.10 0.46 0.08 0.59 0.09 0.54 
RR↑ 
yes 0.02 0.70 0.07 0.23 0.06 0.26 
no -0.04 0.50 -0.03 0.58 0.02 0.75 
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RAS 
blockade 
ACEI -0.01 0.79 -0.02 0.70 -0.04 0.36 
ARB 0.03 0.74 0.14 0.09 0.19 0.02 
Worsening 
CHF 
yes 0.07 0.51 0.20 0.07 0.18 0.11 
no -0.03 0.51 -0.01 0.82 0.02 0.59 
ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; NYHA, New York Heart Association; LVEF, left 
ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; CKD, chronic kidney disease; RR↑, hypertension; RAS, renin 
angiotensin system. 
 
SECONDARY/SAFETY ENDPOINTS 
Of 722 patients included into this study, 90 patients (12%) were hospitalized due to worsening CHF 
throughout the period considered. Of these, 23 patients (3%) decompensated at least twice. 
Hospitalization rates were higher in patients with CKD stage IV as compared to those in CKD stage 
IIIa and IIIb (P = 0.02). There was no relation between ACEI/ARB equivalent dose at baseline and 
hospitalization due to worsening CHF (P = 0.27). However, hospitalization rates differed with respect 
to changes of ACEI/ARB dose equivalents (Table 7). When considering both stage of CKD (stage IIIa 
vs. stage IIIb vs. stage IV) and ACEI/ARB dose equivalent at baseline (low-dose vs. moderate-dose 
vs. high-dose), patients with CKD stage IV and moderate-dose ACEI/ARB therapy at baseline (n = 
17) had the highest hospitalization rate (n = 6). These data, however, should be interpreted with 
caution due to small numbers. 
 
Table 7: Hospitalization due to worsening CHF as a function of ACEI/ARB dosing strategy 
ACEI/ARB dose 
at baseline 
ACEI/ARB dose after 
12 months 
No hospitali-
zation (n, %) 
Hospitalization 
(n, %) 
P-
value 
Low-dose 
(n = 148) 
Withdrawal (n = 20) 17 (85) 3 (15) 
 
Maintenance (n = 63) 50 (79) 13 (21) 
 
Up-titration (n = 65) 57 (88) 8 (12) 
 
Moderate-dose Down-titration (n = 48) 40 (83) 8 (17) 0.04 
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(n = 235) Maintenance (n = 109) 93 (85) 16 (15) 
 
Up-titration (n = 78) 73 (94) 5 (6) 
 
High-dose 
 (n = 339) 
Down-titration (n = 72) 58 (81) 14 (19) 
 
Maintenance (n = 267) 244 (91) 23 (9) 
 
ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; n, number of patients. 
 
During the 12 months observation period, severe hyperkalemia occurred in 24 patients (3%). In 3 
patients, serum potassium levels greater than 5.5 mmol/L were detected twice. There was no relation 
between incidence of hyperkalemia and stage of CKD (P = 0.12), incidence of hyperkalemia and 
baseline ACEI/ARB dose equivalent (P = 0.52), or incidence of hyperkalemia and change of 
ACEI/ARB dose equivalent (P = 0.88).  
 
 
DISCUSSION 
In this large, international sample of systolic CHF out-patients with concomitant stable CKD stage 
III/IV, we investigated the association of ACEI/ARB dosing and long-term renal function. Our main 
findings are that, on average: 
 Dose of ACEIs/ARBs is not associated with severity of renal dysfunction at baseline or at one 
year follow-up. 
 Up-titration from lower doses of ACEI/ARB is not associated with deterioration in renal 
function. 
 Conversely, down-titration from higher doses of ACEI/ARB is not associated with improved 
renal function at one year. 
 These results were consistent across subgroups by age, sex, NYHA functional class, LVEF, 
diabetes, concomitant MRA therapy, stage of CKD, hypertension, and worsening CHF during 
the observation period. 
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 There was no association between baseline ACEI/ARB dose and the occurrence of 
hyperkalemia or worsening CHF during 12 months follow-up. 
 
Even though renal dysfunction is common in CHF, patients with severe concomitant CKD have been 
excluded from many trials investigating RAS blockade in CHF. This leaves the clinician caring for 
patients with CHF and CKD with a certain difficulty regarding individual dosing of ACEIs/ARBs. 
Although subgroup analyses of CHF trials and retrospective registry data suggest that ACEI/ARB 
therapy may improve prognosis in patients with CHF and concomitant CKD (3-7, 19), little is known 
about the effects of ACEI/ARB therapy on renal function in these patients (12, 20).  
In fact, the respective guidelines for the management of CHF and CKD provide the clinician with a 
paradox: While renal guidelines recommend not to discontinue ACEIs/ARBs in patients with an eGFR 
<30 mL/min/1.73m² (16, 17), CHF guidelines advise that ACEI/ARBs should only be initiated when 
eGFR is above 30 mL/min/1.73m² and be stopped if it falls below 20 mL/min/1.73m² (13). This may 
account for the lower utilization of ACEIs/ARBs in clinical practice as eGFR declines (3, 6).  
Our data support the “nephrological“ approach to using of ACEIs/ARBs in patients with CKD stage 
IV rather than concerns from CHF cohorts that use of ACEIs/ARBs might precipitate acute renal 
failure (21, 22). There are surprisingly little data against which to compare our study. De Vecchis et al. 
(23) compared 15 patients on high-dose ACEI treatment with 42 on low-dose. They reported that the 
use of high ACEI/ARB doses predicted acute renal failure. In extension, de Silva et al. showed in 72 
patients with CHF and concomitant renal dysfunction that only one fifth of patients experienced a 
substantial recovery of renal function following ACEI down-titration (12).  
It is here that our study significantly expands current evidence. Not only did we demonstrate the 
absence of any long-term adverse association of high-dose ACEI/ARB therapy with renal function in a 
substantially larger cohort - we were further able to show that up-titration to guideline recommended 
higher target doses was not associated with an adverse effect on long-term renal function, too. The fact 
that this was observed in all pre-specified subgroups further corroborates our findings. In addition, we 
found no association between baseline ACEI/ARB dose and the occurrence of hyperkalemia or 
worsening CHF during 12 months follow-up. This is important for clinical practice as our data argues 
19 
 
 
against withholding ACEI/ARB treatment from CHF patients in advanced CKD on grounds of fear of 
adverse effects on renal function or hyperkalemia.  
A review of 12 randomized clinical trials of ACEIs in hypertensive and/or diabetic patients with renal 
dysfunction (serum creatinine >1.4 mg/dL [123.9 µmol/L]) indirectly supports this notion further (24). 
It found that an acute increase in serum creatinine of up to 30% that stabilized within the first two 
months of ACEI therapy strongly predicted long-term preservation of renal function.  
At last, we found no evidence of a dose-dependent adverse relationship between ACEI/ARB treatment 
and renal function. From our data, we speculate that dose-reduction of ACEIs/ARBs from high doses 
does not appear to improve eGFR in patients with stable renal dysfunction. This again is of great 
clinical importance as it means that dose reduction should not be performed based on eGFR only – 
arguing against a common practice encountered in daily care for these patients. 
 
LIMITATIONS 
A potential limitation of the present study is its observational design. We cannot claim cause and 
effect but merely describe associations. In some cases, ACEI/ARB dose was down-titrated and this 
may have been clinically appropriate for these patients. We cannot comment on possible transient 
GFR changes, nor can we comment on reasons for ACEI/ARB titration. There was, however, no 
systematic relationship between baseline eGFR, ACEI/ARB dosing and long-term renal function. In 
addition, our data are derived from comprehensive out-patient data-bases with close surveillance. 
These data therefore reflect the effect of ACEI/ARB therapy in real-world patients in contrast to those 
selected for randomized trials. This adds to the relevance of our results as differences between study 
cohorts and real world patients are very common and there are no randomized trials examining these 
issues so far.  
As the aim of this study was to investigate the relationship between ACEI/ARB dosing and long-term 
renal function, we only included patients who survived for at least 12 months. Thus, owing to the 
study design, we cannot comment on mortality in this study. Literature, however, provides good 
evidence that RAS blockade reduces mortality in CHF with concomitant CKD (3-7, 19).  
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Our analysis was restricted to patients who were on stable ACEIs/ARBs for at least one month prior to 
study inclusion. Thus, study results may not be transferred to patients with new onset ACEI/ARB 
treatment. In addition, we only included patients with systolic CHF, as heart failure with preserved 
ejection fraction represents a heterogeneous disease that subsumes different etiologies and different 
pathophysiological mechanisms. The long span of patient enrolment in our study covers a period with 
important changes of recommended CHF management. Most importantly, the number of patients with 
concomitant MRA treatment increased, which may adversely affect renal function when added to 
ACEI/ARBs. However, our subgroup analyses showed no relationship between renal function and 
ACEI/ARB dosing irrespective of concomitant MRA therapy.  
In contrast to data from population based studies (25, 26), the prevalence of significant hyperkalemia 
was very low in our study. While previous studies identified age, stage of CKD and RAS blocking 
medication as predictors of hyperkalemia in patients with CHF (25-27), we found no relationship 
between the incidence of hyperkalemia and stage of CKD or ACEI/ ARB treatment.  However, our 
results correspond well to data from randomized ACEI trials who observed hyperkalemia in less than 
2% of patients (24).  It is possible that the quality of care these patients received contributed to the 
apparent safety of using higher doses of ACEI/ARBs in the present study. Moreover, the inclusion of 
patients who were on stable ACEIs/ARBs for at least one month may have resulted in a pre-selection 
of patients who tolerate ACEIs/ARBs. However, in everyday clinical practice, worsening renal 
function or hyperkalemia usually lead to a pause in ACEI/ARB treatment instead of a permanent stop 
of therapy. Therefore, patients with prior complications due to ACEI/ARB treatment may still have 
been included into the present study. 
There is on-going discussion in non-CHF cohorts, whether reducing albuminuria and blood pressure 
should be used as surrogates to estimate the efficacy of renal protection with RAAS inhibitors.(28, 29) 
As we did not measure proteinuria, we cannot comment on this. On the other hand, change in serum 
creatinine is an accepted marker for change in renal function (30, 31). Lastly, as patients included in 
our analysis were mainly white Caucasians, applying the results obtained from our study to other 
populations from different ethnic/racial background may not be reliable. 
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CONCLUSIONS 
In stable out-patients with CHF and CKD stage III/ IV, neither high-dose ACEI/ARB therapy, nor up-
titration to high-dose equivalents was associated with adverse long-term changes in renal function. 
There were no safety concerns to this strategy. Down-titration from high doses, on the other hand, was 
not related to an improvement in renal function. In patients with stable CHF and CKD, up-titration of 
ACEIs/ARBs may therefore be considered even in the presence of moderate to severe renal 
impairment. Until more evidence is acquired, this strategy should be pursued only when patients are 
managed by a system of care that ensures regular checks of renal function and potassium. 
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